Lactobacillus gasseri prevents ibrutinib-associated atrial fibrillation through butyrate
Europace · 2025
DOI: 10.1093/europace/euaf018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, 2025. Verfasst von Ling Shi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Youzheng Street 23#, Nangang District, Harbin 150001, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Gastrointestinal Microbiome, Butyrates, Lactobacillus gasseri. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HMU Marshal Initiative Funding, National Natural Science Foundation of China, First Affiliated Hospital of Harbin Medical University.
Abstract (Originalsprache)
Background
Ibrutinib, a widely used anti-cancer drug, is known to significantly increase the susceptibility to atrial fibrillation (AF). While it is recognized that drugs can reshape the gut microbiota, influencing both therapeutic effectiveness and adverse events, the role of gut microbiota in ibrutinib-induced AF remains largely unexplored.
Method
Utilizing 16S rRNA gene sequencing, faecal microbiota transplantation, metabonomics, electrophysiological examination, and molecular biology methodologies, we sought to validate the hypothesis that gut microbiota dysbiosis promotes ibrutinib-associated AF and to elucidate the underlying mechanisms.
Result
We found that ibrutinib administration pre-disposes rats to AF. Interestingly, ibrutinib-associated microbial transplantation conferred increased susceptibility to AF in rats. Notably, ibrutinib induced a significantly decrease in the abundance of Lactobacillus gasseri (L. gasseri), and oral supplementation of L. gasseri or its metabolite, butyrate (BA), effectively prevented rats from ibrutinib-induced AF. Mechanistically, BA inhibits the generation of reactive oxygen species, thereby ameliorating atrial structural remodelling. Furthermore, we demonstrated that ibrutinib inhibited the growth of L. gasseri by disrupting the intestinal barrier integrity.
Conclusion
Collectively, our findings provide compelling experimental evidence supporting the potential efficacy of targeting gut microbes in preventing ibrutinib-associated AF, opening new avenues for therapeutic interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Youzheng Street 23#, Nangang District, Harbin 150001, China.
- Key Laboratory of Cardiac Diseases and Heart Failure, Harbin Medical University, Harbin 150001, China.
- Heilongjiang Key Laboratory for Metabolic Disorder and Cancer Related Cardiovascular Diseases, Harbin Medical University, Harbin 150081, China.
- Heilongjiang Academy of Medical Science, Institute of Metabolic Disease, Harbin, China.
ORCID-Profile: Kunna Wang, Zhiqi Wang, Yue Li
Förderung
- HMU Marshal Initiative Funding
- National Natural Science Foundation of China
- First Affiliated Hospital of Harbin Medical University
- Heilongjiang Province 'Jiebang guashuai' Science and Technology Research
- Excellent Young Medical Talents Training Fund
Zitieren
APA
Shi, L., Duan, Y., Fang, N., Zhang, N., Yan, S., Wang, K., Hou, T., Wang, Z., Jiang, X., Gao, Q., Zhang, S., Li, Y., Zhang, Y., & Gong, Y. (2025). Lactobacillus gasseri prevents ibrutinib-associated atrial fibrillation through butyrate. Europace. https://doi.org/10.1093/europace/euaf018
Vancouver
Shi L, Duan Y, Fang N, Zhang N, Yan S, Wang K, et al. Lactobacillus gasseri prevents ibrutinib-associated atrial fibrillation through butyrate. Europace. 2025. doi:10.1093/europace/euaf018
BibTeX
@article{Shi2025,
author = {Shi, Ling and Duan, Yu and Fang, Ning and Zhang, Ning and Yan, Sen and Wang, Kunna and Hou, Te and Wang, Zhiqi and Jiang, Xiaohui and Gao, Qianhui and Zhang, Song and Li, Yue and Zhang, Yun and Gong, Yongtai},
title = {Lactobacillus gasseri prevents ibrutinib-associated atrial fibrillation through butyrate},
journal = {Europace},
year = {2025},
doi = {10.1093/europace/euaf018}
}
EUVIMED